Cyclin-Dependent Kinase 4
"Cyclin-Dependent Kinase 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cyclin-dependent kinase 4 is a key regulator of G1 PHASE of the CELL CYCLE. It partners with CYCLIN D to phosphorylate RETINOBLASTOMA PROTEIN. CDK4 activity is inhibited by CYCLIN-DEPENDENT KINASE INHIBITOR P16.
| Descriptor ID |
D051358
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.646.500.875 D12.644.360.250.451 D12.776.167.200.451 D12.776.476.250.451
|
| Concept/Terms |
Cyclin-Dependent Kinase 4- Cyclin-Dependent Kinase 4
- Cyclin Dependent Kinase 4
- Cdk4 Cyclin-Dependent Kinase
- Cdk4 Cyclin Dependent Kinase
- Cyclin-Dependent Kinase, Cdk4
- Cdk4 Protein
- Cdk4 Protein Kinase
- Protein Kinase, Cdk4
- p34PSK-J3 Kinase
- p34PSK J3 Kinase
- Cell Division Protein Kinase 4
- PSK-J3 Kinase
- PSK J3 Kinase
- Cyclin D-Dependent Kinase CDK4
- Cyclin D Dependent Kinase CDK4
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase 4".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase 4".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase 4" by people in this website by year, and whether "Cyclin-Dependent Kinase 4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase 4" by people in Profiles.
-
Cyclin-dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database. Int J Cancer. 2025 Apr 01; 156(7):1404-1418.
-
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA. Pharmacoeconomics. 2023 06; 41(6):709-718.
-
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer. 2023 04 01; 129(7):1051-1063.
-
Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast Cancer Res Treat. 2023 Feb; 198(1):159-166.